Epigenetic regulation by lysine demethylase 5 (KDM5) enzymes in cancer

Lauren P. Blair, Jian Cao, Mike Ran Zou, Joyce Sayegh, Qin Yan

Research output: Contribution to journalReview articlepeer-review

121 Scopus citations


Similar to genetic alterations, epigenetic aberrations contribute significantly to tumor initiation and progression. In many cases, these changes are caused by activation or inactivation of the regulators that maintain epigenetic states. Here we review our current knowledge on the KDM5/JARID1 family of histone demethylases. This family of enzymes contains a JmjC domain and is capable of removing tri- and di- methyl marks from lysine 4 on histone H3. Among these proteins, RBP2 mediates drug resistance while JARID1B is required for melanoma maintenance. Preclinical studies suggest inhibition of these enzymes can suppress tumorigenesis and provide strong rationale for development of their inhibitors for use in cancer therapy.

Original languageEnglish (US)
Pages (from-to)1383-1404
Number of pages22
Issue number1
StatePublished - Mar 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • Cancer stem cell
  • Drug resistance
  • Histone demethylase
  • JARID1
  • KDM5
  • Lid
  • PLU1
  • RBP2
  • SMCX
  • SMCY


Dive into the research topics of 'Epigenetic regulation by lysine demethylase 5 (KDM5) enzymes in cancer'. Together they form a unique fingerprint.

Cite this